Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
38,743
datasets available to search
ShareScore release 0.9.0
Dataset results
38,743 results for “efficacy”
Data from: Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
<p>Morbidity and mortality attributable to COVID-19 is devastating global health systems and economies. Bacillus Calmette Guérin (BCG) vaccination has been in use for many decades to prevent severe forms of tuberculosis in children. Studies have also shown a combination of improved long-term innate or trained immunity (through epigenetic reprogramming of myeloid cells) and adaptive responses after BCG vaccination, which leads to non-specific protective effects in adults. Observational studies have shown that countries with routine BCG vaccination programs have significantly less reported cases and deaths of COVID-19, but such studies are prone to significant bias and need confirmation. To date, in the absence of direct evidence, WHO does not recommend BCG for the prevention of COVID-19. This project aims to investigate in a timely manner whether and why BCG-revaccination can reduce infection rate and/or disease severity in health care workers during the SARS-CoV-2 outbreak in South Africa. </p> <p>These objectives will be achieved with a blinded, randomised controlled trial of BCG revaccination versus placebo in exposed front-line staff in hospitals in Cape Town. Observations will include the rate of infection with COVID-19 as well as the occurrence of mild, moderate or severe ambulatory respiratory tract infections, hospitalisation, need for oxygen, mechanical ventilation or death. HIV-positive individuals will be excluded. Safety of the vaccines will be monitored. A secondary endpoint is the occurrence of latent or active tuberculosis. Initial sample size and follow-up duration is at least 500 workers and 52 weeks. Statistical analysis will be model-based and ongoing in real time with frequent interim analyses and optional increases of both sample size or observation time, based on the unforeseeable trajectory of the South African COVID-19 epidemic, available funds and recommendations of an independent data and safety monitoring board. The study will be supported by a novel 3D lung organoid model of SARS-CoV-2 infection system that can mimic the cascade of immunological events after SARS-CoV-2 infection to determine and analyse the contribution of cellular components to the impact of BCG revaccination in this study.</p> <p>Given the immediate threat of the SARS-CoV-2 epidemic the trial has been designed as a pragmatic study with highly feasible endpoints that can be continuously measured. This allows for the most rapid identification of a beneficial outcome that would lead to immediate dissemination of the results, vaccination of the control group and outreach to the health authorities to consider BCG vaccination for all qualifying health care workers.</p>
The Efficacy of Daily versus Weekly Ferrous Sulfate in Maintaining Normal Serum Ferritin Levels During Pregnancy: A Randomized Controlled Trial
<p>Serum ferritin is the most reliable indication of stored iron in pregnancy, offering a<br>noninvasive way to detect iron deficiency anemia before it occurs. Therefore, this study aimed to<br>determine serum ferritin levels among women receiving daily versus weekly iron supplementation,<br>with a secondary focus on comparing the proportion developing iron deficiency anemia and compli-<br>ance rates between the two groups.<br>Methods: This non-blinded randomized control trial involved non-anaemic pregnant women attend-<br>ing antenatal clinics at two Teaching Hospitals in Osun State. One hundred twenty-five subjects were<br>recruited to receive 65mg in the control group, while another 125 subjects in the active group re-<br>ceived three tablets (195mg) of ferrous sulfate (Fesulf) once weekly for 17 weeks from the 20th to<br>37th weeks of gestation. The primary outcome measure was comparing mean serum ferritin levels in<br>both groups at 37 weeks.<br>Results: Among the 240 subjects analyzed, the 37-week serum ferritin level was higher in the daily<br>group (73.26±26.67µg/L) compared to the weekly group (63.04±30.71 µg/L), p value=0.006. Four<br>(3.36%) and 10 (8.26%) of our subjects had Iron deficiency anaemia. Nine subjects (3.75%) reported<br>dyspepsia as a side effect. Daily 65 mg of Felsulf proved more effective than weekly 195mg in main-<br>taining normal blood ferritin levels during pregnancy.<br>Conclusions: Daily iron supplementation with 65mg ferrous sulfate was more effective at main-<br>taining adequate maternal iron concentration in this group of non-anaemic pregnant women. This<br>dosage is recommended for routine iron supplementation in our environment.</p>
Efficacy of inhibitor on wild-type ACVR1 and R206H mutant in C2C12 cells (by DLA)
<p>There are concerns that compounds that are effective in inhibiting ALK2 by occupying its ATP-binding pocket might have reduced efficacy against mutant ALK2. That will be undesirable since the compounds should also target the mutant gain-of-function ALK2 in DIPG cells. The following experiment takes advantage of the fact that ALK2-R206H mutant confers a neofunction of being activated by Activin A (not activating towards wild-type ALK2). Therefore, using Activin A as the stimulation ligand, the effectiveness of inhibition on ALK2-R206H can be specifically determined. BMP6 which activates both wild-type ALK2 and ALK2-R206H is also included.</p>
H1N1 A/Netherlands/602/2009 challenge data to assess efficacy of universal flu candidates FL H1#2316 and UFV#4157
<p>Purpose:<br> This H1N1 A/Netherlands/602/2009 challenge was performed to assess if B- and T- cell subsets frequencies kinetics of mature B-cell subsets residing in the iliac lymph nodes after immunization, can predict the protective efficacy of the used immunization regimen this murine challenge model.</p> <p>Method:<br> We compared B and T cell subset frequencies between cohorts of mice subjected to immunization regimens inducing different levels of protection against lethal H1N1 influenza challenge. Naïve 8-weeks old mice were immunized three times, at days 0, 21 and 42 with different immunogens. One cohort of animals was vaccinated received a largely protective vaccine containing a high dose (30 µg) of a trimeric full-length H1 HA antigen (FL H1#2316) that provides heterologous protection against H1N1 A/Netherlands/602/2009 while a second cohort received a minimally protective vaccine containing a high dose (30 µg) of an HA stem-based monomeric antigen (UFV#4157) derived from FL H1#2316 To control for differences in immune responses related to the dose rather than intrinsically protective properties of the used immunization antigen, a lower but partiallly protective protective dose (0.3 µg) of FL H1#2316 was used for immunizations of a third cohort, while as a negative control for survival a fourth cohort was immunized with PBS only. All immunizations, including mock-immunizations with PBS, were adjuvanted with alum. To analyze cellular responses at early and late timepoints of GC reactions after prime or boost immunizations, 8 animals per cohort were sacrificed at 8 different timepoint (days 4, 7, 12, 19, 25, 28, 46 and 49). To assess the protective efficacy of the administered vaccine regimens, 10 animals per immunized cohort were challenged intranasally with a lethal dose of 25xLD50 H1N1 A/Netherlands/602/2009, heterologous to the parental H1 virus strain.<br> <br> Results:<br> After influenza challenge we observed that high (30 µg) and low (0.3 µg) doses of FL H1#2316 conferred survival rates of 80% and 60% respectively, while a high dose (30 µg) of UFV#4157 failed to provide any protection. All the animals that received PBS immunization succumbed to the infection.</p> <p>For further results regarding B and T cell expansion, please review the publication.</p>
Figure1 in Potential of Biocontrol Efficacy of Entomopathogenic Nematodes on White Grubs, Anomalacommunis (Coleoptera: Scarabaeidae) in Potato
Figure1. Bioefficacy of entomopathogenic nematodes against A. Communis under field conditions
Fig1 in Potential of Biocontrol Efficacy of Entomopathogenic Nematodes on White Grubs, Anomalacommunis (Coleoptera: Scarabaeidae) in Potato
Fig1. Bioefficacy of entomopathogenic nematodes against A. communis on potato
Fig. 2 in Field efficacy of insecticides for management of invasive fall armyworm, Spodoptera frugiperda (J. E. Smith) (Lepidoptera: Noctuidae) on maize in India
Fig. 2. Corn yield in field efficacy treatments in Sep planted crop in 2018.
Fig. 1 in Field efficacy of insecticides for management of invasive fall armyworm, Spodoptera frugiperda (J. E. Smith) (Lepidoptera: Noctuidae) on maize in India
Fig. 1. Corn yield in field efficacy treatments in Jun planted crop in 2018.
Dataset related to article "Tumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells"
<p>This record contains data related to article “Tumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells”</p> <p><span>Tumor Treating Fields (TTFields) applied with standard chemotherapy have been approved for the first-line treatment of unresectable pleural mesothelioma (PM), an aggressive malignancy with limited effective therapy options.</span></p> <p><span>In this study, we demonstrated that the simultaneous exposure to TTFields and doxorubicin or vinorelbine enhanced treatment efficacy in patient-derived PM cells by increasing intracellular drug concentrations. This was achieved by modulating several genes that encode transport proteins, such as the downregulation of P-glycoprotein.</span></p> <p><span>Using specific, sensitive and quantitative analytical techniques, we observed a more than 70% increase in intracellular concentrations of doxorubicin and vinorelbine in samples treated with TTFields, and a greater than 50% increase in drug uptake in cells exposed to TTFields and pemetrexed. This result indicates that the increased drug concentration observed in TTFields treated cells is significant not only for drugs that are P-gp substrates but also suggests that TTFields could potentially affect other efflux pumps. However, the co-exposure to the drug and TTFields was critical to increasing intracellular drug levels, highlighting the necessity of concurrent use with drugs to enhance the antiproliferative effects of treatment.</span></p> <p><span>The <em>in vitro</em> findings were further corroborated by <em>in vivo</em> pharmacokinetic experiments in mice subcutaneously injected with epithelioid PM tumors. Indeed, a 30% increase in intratumor concentrations was observed when vinorelbine was administered with TTFields.</span></p> <p><span>Our findings suggest that TTFields could be a well-tolerated approach for enhancing intratumoral drug levels and potentially achieving a more significant therapeutic impact on PM treatment.</span></p>
Genomic data from a pharmacogenetic study based on the efficacy of Tocilizumab in severe COVID-19 patients
<p>These data correspond to a pharmacogenetic study aimed to explore genetic associations related to the efficacy of Tocilizumab in severe COVID-19 patients. The study comprised two sets of patients, an initial subset consisted of 425 patients to whom a in-dpeth sequencing of a thermofisher sequencing panel of immune-related genes was performed, as well as a second set of 245 patients with the information of the genotyping of three selected SNPs</p>
Data for "Designing protein nano-construct in ionic liquid: a boost in efficacy of cytochrome C under stresses"
<p>The dataset provides the raw data for the figures reported in the manuscript entitled "Designing protein nano-construct in ionic liquid: a boost in efficacy of cytochrome C under stresses". Data are provided for silk nanofibrils and protein nano-construct characterization, activity assay of cytochrome c under various conditions, and stability study using CD spectroscopy in .xlsx and .opju format. </p>
The Efficacy of Azithromycin in the Treatment of Influenza A infection: A Systematic Review
<p>Background:</p> <p>The WHO recommendation against the use of macrolides reflects the little low-quality evidence about the effect of azithromycin (AZ) on influenza A infection. Considering recent reports about AZ use despite the WHO's unfavorable recommendations, we aimed to test the evidence for the usage of AZ in the treatment of influenza A infection.</p> <p>Methods:</p> <p>Various online databases were searched till August 2023 and thorough text and evidence evaluation resulted in selecting 7 studies.</p> <p>Results:</p> <p>The selected reports included randomized control trials (two), cohort (three), case/control (one) studies, and one case report. Pooling of the results was unattainable due to the variability among studies in patient criteria, study outcomes, and study designs. Based on the limited reports with insufficient evidence, a recommendation for the use of AZ in the treatment regimen was not possible despite the associated reduction in inflammatory cytokines by AZ administration and the absence of significant adverse effects or mortality in hospital-admitted or ICU patients. While these findings support the current guidelines for the treatment of influenza A infection, the evidence behind these guidelines and treatment characteristics were illustrated.</p> <p>Conclusion:</p> <p>AZ shows a potential symptom improvement and pro-inflammatory laboratory indices in influenza A patients. Another positive aspect is the absence of complications associated with AZ administration to critically ill patients and acceptable prognosis. However, it is crucial to have more quality research on this matter that focuses on the indication of the use of AZ, and the timing of initiation, dosage, and duration of treatment while monitoring adverse events.</p>
Table 7 in Efficacy of Actellic 300 CS-based indoor residual spraying on key entomological indicators of malaria transmission in Alibori and Donga, two regions of northern Benin
<p><b>Table 7</b> Indoor density of <i>An. gambiae</i> (<i>s.l</i>.) in IRS and control areas</p><table><tbody><tr><th>Period</th><th>Area</th><th>No. of rooms</th><th>No. collected</th><th>Density/room</th><th><i>P</i> -value</th></tr></tbody><tbody><tr><th>Before IRS (June–October 2016)</th><td>Baseline</td><td>610</td><td>1001</td><td>1.64</td><td><0.0001</td></tr><tr><th>After 1st round of IRS (June–October 2017)</th><td>After IRS areas</td><td>673</td><td>273</td><td>0.41</td><td></td></tr><tr><th>After 1st round of IRS (June–September 2017)</th><td>After IRS areas</td><td>551</td><td>208</td><td>0.38</td><td><0.0001</td></tr><tr><th></th><td>Control areas</td><td>160</td><td>244</td><td>1.53</td><td></td></tr><tr><th>After 2nd round of IRS (June–August 2018)</th><td>After IRS areas</td><td>242</td><td>117</td><td>0.48</td><td><0.0001</td></tr><tr><th></th><td>Control areas</td><td>88</td><td>155</td><td>1.76</td><td></td></tr></tbody></table>
Table 4 in Efficacy of Actellic 300 CS-based indoor residual spraying on key entomological indicators of malaria transmission in Alibori and Donga, two regions of northern Benin
<p><b>Table 4</b> Biting location of <i>An. gambiae</i> (<i>s.l</i>.) in IRS and control areas</p><table><tbody><tr><th>Period</th><th>Area</th><th>Location</th><th>No. collected</th><th>Person/night</th><th>HBR (b/p/n)</th><th><i>P</i> -value</th></tr></tbody><tbody><tr><th>Before IRS (June–October 2016)</th><td>Future IRS</td><td>Indoor</td><td>1156</td><td>128</td><td>9.03</td><td>0.00098</td></tr><tr><th></th><td></td><td>Outdoor</td><td>1002</td><td>128</td><td>7.83</td><td></td></tr><tr><th>After 1st IRS round (June–September 2017)</th><td>IRS</td><td>Indoor</td><td>544</td><td>112</td><td>4.86</td><td><0.0001</td></tr><tr><th></th><td></td><td>Outdoor</td><td>1150</td><td>112</td><td>10.27</td><td></td></tr><tr><th></th><td>Control</td><td>Indoor</td><td>678</td><td>52</td><td>13.04</td><td><0.0001</td></tr><tr><th></th><td></td><td>Outdoor</td><td>446</td><td>52</td><td>8.58</td><td></td></tr><tr><th>After 2nd IRS round (June–August 2018)</th><td>IRS</td><td>Indoor</td><td>599</td><td>80</td><td>7.49</td><td>0.233</td></tr><tr><th></th><td></td><td>Outdoor</td><td>642</td><td>80</td><td>8.03</td><td></td></tr><tr><th></th><td>Control</td><td>Indoor</td><td>568</td><td>40</td><td>14.2</td><td><0.0001</td></tr><tr><th></th><td></td><td>Outdoor</td><td>313</td><td>40</td><td>7.83</td><td></td></tr></tbody></table><p><i>AbbreviatioNS</i>: HBR,human biting rate;b/p/n,bite/person/night</p>
Table 1 in Efficacy of Actellic 300 CS-based indoor residual spraying on key entomological indicators of malaria transmission in Alibori and Donga, two regions of northern Benin
<p><b>Table 1</b> <i>Anopheles</i> species composition in surveyed areas before and after IRS</p><table><tbody><tr><th>Species</th><th>Before IRS (May 2016–April 2017)</th><th>After 1st round of IRS (June 2017–March 2018)</th><th>Control (Bembereke, Kouande)</th><th>After 2nd round of IRS (June 2018–November 2018)</th><th>Control (Bembereke– Kouande)</th><th>Total</th></tr></tbody><tbody><tr><th><i>An.gambiae</i> (<i>s.l</i>.)</th><td>2465</td><td>2379</td><td>1546</td><td>1286</td><td>929</td><td>8605</td></tr><tr><th><i>An.funestus</i></th><td>54</td><td>54</td><td>16</td><td>9</td><td>7</td><td>140</td></tr><tr><th><i>An.coustani</i></th><td>9</td><td>0</td><td>0</td><td>0</td><td>0</td><td>9</td></tr><tr><th><i>An.pharoensis</i></th><td>3</td><td>2</td><td>5</td><td>2</td><td>3</td><td>15</td></tr><tr><th><i>An.paludis</i></th><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><th><i>An.nili</i></th><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td></tr><tr><th><i>An.ziemanni</i></th><td>2</td><td>2</td><td>0</td><td>1</td><td>0</td><td>5</td></tr><tr><th>Total</th><td>2534</td><td>2437</td><td>1567</td><td>1299</td><td>939</td><td>8776</td></tr></tbody></table>
Table 3 in Efficacy of Actellic 300 CS-based indoor residual spraying on key entomological indicators of malaria transmission in Alibori and Donga, two regions of northern Benin
<p><b>Table 3</b> Parity rates of <i>Anopheles gambiae</i> (<i>s.l</i>.) collected before and after the first round IRS</p><table><tbody><tr><th>IRS area</th><th>Variable</th><th>Before IRS (June–October 2016)</th><th>After 1st round of IRS (June– October 2017)</th><th><i>Χ</i> 2-value</th><th><i>P</i> -value</th></tr></tbody><tbody><tr><th>Alibori-Donga</th><td>No. dissected</td><td>1422</td><td>1214</td><td>–</td><td>–</td></tr><tr><th></th><td>No. parous</td><td>996</td><td>457</td><td>–</td><td>–</td></tr><tr><th></th><td>Parous (%)</td><td>70.04</td><td>37.64</td><td>276.57</td><td><0.0001</td></tr></tbody></table>
Table 2 in Efficacy of Actellic 300 CS-based indoor residual spraying on key entomological indicators of malaria transmission in Alibori and Donga, two regions of northern Benin
<p><b>Table 2</b> Frequency of sibling species of the <i>An. gambiae</i> (<i>s.l.</i>) complex in IRS and control areas</p><table><tbody><tr><th>Period</th><th>No. of</th><th>Alibori (IRS Area 1)</th><th></th><th>Donga (IRS Area 2)</th><th></th><th>Total (IRS Areas)</th><th></th><th>Bembereke (Control area)</th></tr></tbody><tbody><tr><th></th><td>analysed samples in IRS areas</td><td><i>An. gambiae</i></td><td><i>An.coluzzii</i></td><td><i>An. arabiensis</i></td><td><i>An. gambiae</i></td><td><i>An. coluzzii</i></td><td><i>An. arabiensis</i></td><td><i>An. gambiae</i></td><td><i>An. coluzzii</i></td><td><i>An. arabiensis</i></td><td><i>An. gambiae</i></td><td><i>An. coluzzii</i></td><td><i>An.arabiensis</i></td></tr><tr><th>Before IRS (May 2016–October 2016)</th><td>980</td><td>170</td><td>271</td><td>0</td><td>387</td><td>152</td><td>0</td><td>557</td><td>423</td><td>0</td><td>–</td><td>–</td><td>–</td></tr><tr><th>After IRS (June 2017–November 2018)</th><td>1794</td><td>466</td><td>176</td><td>17</td><td>520</td><td>147</td><td>5</td><td>986</td><td>323</td><td>22</td><td>277</td><td>181</td><td>5</td></tr><tr><th>Proportion (%)</th><td>–</td><td>70.71</td><td>26.70</td><td>2.57</td><td>77.38</td><td>21.87</td><td>0.74</td><td>74.07</td><td>24.26</td><td>1.65</td><td>59.82</td><td>39.09</td><td>1.07</td></tr><tr><th>Total (Before+after IRS)</th><td>2774</td><td>636</td><td>447</td><td>17</td><td>907</td><td>299</td><td>5</td><td>1543</td><td>746</td><td>22</td><td>277</td><td>181</td><td>5</td></tr><tr><th>Proportion (%)</th><td>–</td><td>57.81</td><td>40.63</td><td>1.54</td><td>74.89</td><td>24.69</td><td>0.41</td><td>66.76</td><td>32.28</td><td>0.95</td><td>59.82</td><td>39.09 1.07</td></tr></tbody></table>
Table 8 in Efficacy of Actellic 300 CS-based indoor residual spraying on key entomological indicators of malaria transmission in Alibori and Donga, two regions of northern Benin
<p><b>Table 8</b> Blood-feeding rates in <i>An. gambiae</i> (<i>s.l.</i>) in treated and control areas</p><table><tbody><tr><th>Period</th><th>Area</th><th>No. collected</th><th>Unfed</th><th>Fed</th><th>Gravid</th><th>Half-gravid</th><th>Bloodfeeding rate %</th><th><i>P</i> -value</th></tr></tbody><tbody><tr><th>Before IRS:June–October 2016</th><td>IRS areas</td><td>1001</td><td>26</td><td>922</td><td>12</td><td>41</td><td>96.20</td><td><0.0001</td></tr><tr><th>After 1st round of IRS:June–October 2017</th><td></td><td>273</td><td>99</td><td>171</td><td>1</td><td>2</td><td>63.37</td><td></td></tr><tr><th>After 1st round of IRS:June–September 2017</th><td>IRS areas</td><td>208</td><td>78</td><td>129</td><td>0</td><td>1</td><td>62.5</td><td><0.0001</td></tr><tr><th></th><td>Control areas</td><td>244</td><td>16</td><td>187</td><td>31</td><td>10</td><td>80.74</td><td></td></tr></tbody></table>
Table 6 in Efficacy of Actellic 300 CS-based indoor residual spraying on key entomological indicators of malaria transmission in Alibori and Donga, two regions of northern Benin
<p><b>Table 6</b> Human-biting rate, sporozoite index and entomological inoculation rate in IRS and control areas</p><table><tbody><tr><th>Variable</th><th>After 1st IRS campaign (June–September 2017)</th><th>After 2nd IRS campaign (June–August 2018)</th></tr></tbody><tbody><tr><th></th><td>IRS areas</td><td>Control areas</td><td>Reduction (%)</td><td>IRS areas</td><td>Control areas</td><td>Reduction (%)</td></tr><tr><th></th><td>(Alibori–Donga)</td><td>(Bembereke–Kouande)</td><td>(Alibori–Donga)</td><td>(Bembereke–Kouande)</td></tr><tr><th>HBR/night</th><td>7.56</td><td>10.81</td><td>–</td><td>7.76</td><td>11.01</td><td>–</td></tr><tr><th>SI (%)</th><td>0.71</td><td>3.7</td><td>80.81</td><td>0.6</td><td>3</td><td>80</td></tr><tr><th>EIR (ib/person/night)</th><td>0.053</td><td>0.403</td><td>–</td><td>0.05</td><td>0.325</td><td>–</td></tr><tr><th>EIR (ib/person/month)</th><td>1.6</td><td>12.11</td><td>86.78</td><td>1.5</td><td>9.75</td><td>84.61</td></tr></tbody></table><p><i>AbbreviatioNS</i>: SI,sporozoite index;HBR,human-biting rate;EIR,entomological inoculation rate;ib,infective bite</p>
Table 5 in Efficacy of Actellic 300 CS-based indoor residual spraying on key entomological indicators of malaria transmission in Alibori and Donga, two regions of northern Benin
<p><b>Table 5</b> Human-biting rate, sporozoite index and entomological inoculation rate in Alibori and Donga regions (IRS areas) before and after the first round of IRS 2017</p><table><tbody><tr><th>Region</th><th>Variable</th><th>Before IRS (June–October 2016)</th><th>After 1st round of IRS (June– October 2017)</th><th>Reduction (%)</th></tr></tbody><tbody><tr><th>IRS areas (Alibori, Donga)</th><td>HBR/night</td><td>8.43</td><td>7.37</td><td>–</td></tr><tr><th></th><td>SI (%)</td><td>8.4</td><td>1.2</td><td>85.71</td></tr><tr><th></th><td>EIR (ib/person/night)</td><td>0.707</td><td>0.09</td><td>–</td></tr><tr><th></th><td>EIR (ib/person/month)</td><td>21.21</td><td>2.7</td><td>87.27</td></tr></tbody></table><p><i>AbbreviatioNS</i>: SI,sporozoite index;HBR,human-biting rate;EIR,entomological inoculating rate;ib,infected bite</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.